Weekender 3/11/16

This edition of the BioLines Weekender once again features the wide breadth of innovation taking place within our State.

Over the last two weeks, there were a number of new FDA designations and drug approvals going to BioNJ Members, including Allergan, Bristol-Myers Squibb, Matinas BioPharma, Merck and Novartis. See more below.

With approximately 2,300 clinical trials taking place within New Jersey, positive results are being reported from companies, such as Advaxis, ContraVir Pharmaceuticals, Eli Lilly and Novo Nordisk, giving new hope for Patients everywhere. Other great news comes from Cancer Genetics, Celgene, Genmab, Immunomedics, Ipsen and Taiho Pharmaceuticals.

Additionally, new research, licensing opportunities and companies continue to roll out from our academic institutions.

Please take a look at BioNJ’s upcoming calendar of educational programs, perfect for finding new partners, networking with colleagues and friends, brainstorming ideas and staying on the cutting edge.


Click here to read this week’s Weekender.